Triplet Induction + 1 or 2-Drug Maintenance
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
Arms / Cohorts
Active Comparator:Arm I: Bortezomib + Lenalidomide + Dexamethasone + Lenalidomide Maintenance
Accepting patients
Experimental:Arm II: Daratumumab + Lenalidomide + Dexamethasone + Lenalidomide Maintenance
Accepting patients
Experimental:Arm III: Daratumumab + Lenalidomide + Dexamethasone + Daratumumab and Lenalidomide Maintenance
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.